Vit D and PD-1 Blockade; Low Implant-Related SCC Risk; Better Pay for Unused Meds

Patients with advanced melanoma had a higher response rate with immunotherapy when they had normal vitamin D levels either at baseline or through supplementation. (Cancer)

Foghorn Therapeutics announced a pause in enrollment in a phase I trial of the investigational drug FHD-609 for synovial sarcoma to investigate a potential safety issue.

The National Comprehensive Cancer Network has published a new patient education resource about inflammatory breast cancer.

A study of more than 50,000 women with breast cancer showed only one case of breast implant-associated squamous cell carcinoma during more than 4 years of follow-up. (JAMA Surgery)

Tips on how to get better Medicare reimbursement for unused cancer medications. (Oncology Business Review)

Novartis announced FDA clearance to begin production of the radiopharmaceutical lutetium ¹⁷⁷Lu vipivotide tetraxetan (Pluvicto), used to treat metastatic castration-resistant prostate cancer, at its factory in Millburn, New Jersey. (BioPharma Dive)

An investigational fluorescence imaging system showed potential for identifying residual cancer after lumpectomy for breast cancer, even when pathology indicated clear surgical margins. (Lumicell, NEJM Evidence)

Cancer survivors with transportation barriers to care have an increased likelihood of emergency room visits and an increased mortality risk. (American Cancer Society, Journal of the National Cancer Institute)

Older women treated for breast cancer derived little benefit from regular mammographic follow-up. (American Society of Breast Surgeons)